Efficacy and Safety of Flutiform K-haler in Patients With Uncontrolled Asthma Following Mid-dose ICS/LABA DPI Therapy

Summary

The purpose of this study is to evaluate the efficacy of the Asthma improvement of Flutiform K-haler after 12 weeks of treatment in patients with moderate to severe uncontrolled\* asthma following mid-dose ICS/LABA DPI therapy.

Timeline

Start

2019-11-26

Primary completion

2020-09-14

Completion

2020-09-14

Outcome

Outcome not reported

Stopped: “The Contract of K-haler products had been terminated between Mundipharma and provider. Therefore, this clinical trial was terminated early.”

Drugs

Indications